search
Back to results

The Hysteroscopic Morcellator (HM). (HM)

Primary Purpose

Large Intrauterine Polyps, Smaller Type 0 and 1 Myomas, Residual Placental Tissue

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Hysteroscopic morcellator
Resectoscope
Sponsored by
University Hospital, Ghent
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Large Intrauterine Polyps focused on measuring intrauterine polyps, myomas, residual placental tissue

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with one or more intrauterine polyp(s) with a diameter ≥ 1 cm as seen on ultrasound, confirmed by saline infusion sonography and/or ambulant diagnostic hysteroscopy who are planned for hysteroscopic surgery.
  • Patients with one or more intrauterine myoma(s) with a diameter ≤ 3 cm as seen on ultrasound, confirmed by saline infusion sonography and/or ambulant diagnostic hysteroscopy who are planned for hysteroscopic surgery.
  • Patients with residual placental tissue as seen by ambulant diagnostic hysteroscopy who are planned for hysteroscopic surgery.

Exclusion Criteria:

  • Only polyps < 1cm (Note: intrauterine polyps < 1 cm are treated in an ambulatory setting).
  • Myomas with a diameter > 3 cm (Note: Myomas > 3 cm are treated with resectoscopy)
  • Type 2 myomas
  • Visual or pathological (e.g. on biopsy) evidence of malignancy preoperatively or at the time of operation.
  • Untreated cervical stenosis making safe access for operative hysteroscopy impossible as diagnosed preoperatively or at the time of operation.
  • With a contra-indication for operative hysteroscopy.

Sites / Locations

  • Ghent University Hospital
  • Catharina Hospital Eindhoven

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

hysteroscopic morcellator

Resectoscope

Arm Description

Women, randomized into getting a treatment with the hysteroscopic morcellator.

Women, randomized into getting a treatment with the resectoscope.

Outcomes

Primary Outcome Measures

Installation time and operating time.
Installation time is defined as the time to set up the hysteroscopic instrumentation ready for use (time from start of setting up the instrumentation to start resection / morcellation). Operating time is defined as the time starting visual introduction of the hysteroscope until the time at which the procedure is completed and the hysteroscope is removed definitely. Times will be measured with a stop watch by a trained nurse.
Check for adhesions during follow-up.
Ambulant diagnostic hysteroscopy is performed at 6 weeks postoperative follow-up.

Secondary Outcome Measures

Fluid deficit
Fluid deficit in both procedures is the result of subtracting the outflow volumes from the inflow volumes as measured by the pump.
complications and complaints
During the postoperative hospital stay blood samples looking for electrolyte imbalances will only be taken when excessive fluid absorption is suspected based on fluid deficit (> 2500 mL for normal saline) and/or clinical symptoms. At 6 weeks postoperatively a standard visit is scheduled. Complications and complaints are recorded, and ultrasound is performed.

Full Information

First Posted
February 15, 2012
Last Updated
February 3, 2021
Sponsor
University Hospital, Ghent
search

1. Study Identification

Unique Protocol Identification Number
NCT01537822
Brief Title
The Hysteroscopic Morcellator (HM).
Acronym
HM
Official Title
The Hysteroscopic Morcellator Versus the Bipolar Resectoscope for Removal of Lager Intrauterine Polyps, Removal of Submucous Myomas and Removal of Residual Placental Tissue: a Randomized Controlled Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
May 2011 (undefined)
Primary Completion Date
July 1, 2018 (Actual)
Study Completion Date
July 1, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Ghent

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Rationale: The hysteroscopic morcellator (HM) is a novel technique for removal of intrauterine polyps, myomas and placental tissue. It withholds some technical advantages over resectoscopy. Previous data suggest that it's a faster technique than the latter, and shows that it has a low complication rate. Objective: To compare the HM to bipolar resectoscopy for removal of: 1) large intrauterine polyps, 2) smaller type 0 and 1 myomas, 3) residual placental tissue, in terms of efficiency and complications. Study design: Single blind, randomized controlled multicenter trial. Study population: Women aged over 18 years old with: 1) large (≥ 1 cm) intrauterine polyps, 2) smaller (≤ 3 cm) type 0 or 1 myomas, 3) residual placental tissue, who are planned for hysteroscopic removal. Intervention: Patients are randomized between removal with the HM or the bipolar resectoscope. Main study parameters/endpoints: Installation and operating time. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Women who are referred to our polyclinic will be seen on a first visit, and, according to the standard work-up, an ultrasound will be performed when intrauterine pathology is suspected. To confirm the diagnosis a saline infusion sonography (SIS) and/or ambulant diagnostic hysteroscopy will be performed consequently. Once the diagnosis is confirmed and surgery is planned, women will be asked whether they want to take part in this study. At this moment, both techniques are used in our hospitals and the choice of treatment depends on the preference of the gynaecologist. All women will be treated with operative hysteroscopy in a daycare setting according to the standard of care, only now randomized between the two techniques. A standard postoperative visit with ultrasound examination and/or ambulant diagnostic hysteroscopy is scheduled 6 weeks later. Late postoperative complications and complaints are recorded. It is expected that the HM beholds some advantages over the bipolar resectoscope such as shorter operating time and less complications (e.g. risk of perforation, current and fluid related complications). Previous data do not demonstrate any additional risks related to the use of the HM. Moreover we will check whether the HM has a lower risk of intrauterine adhesion formation, as this might influence patient's fertility. After completion of the RCT, an observational study is planned considering pregnancies subsequent to the hysteroscopic procedure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Large Intrauterine Polyps, Smaller Type 0 and 1 Myomas, Residual Placental Tissue
Keywords
intrauterine polyps, myomas, residual placental tissue

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
253 (Actual)

8. Arms, Groups, and Interventions

Arm Title
hysteroscopic morcellator
Arm Type
Experimental
Arm Description
Women, randomized into getting a treatment with the hysteroscopic morcellator.
Arm Title
Resectoscope
Arm Type
Active Comparator
Arm Description
Women, randomized into getting a treatment with the resectoscope.
Intervention Type
Procedure
Intervention Name(s)
Hysteroscopic morcellator
Intervention Description
Morcellation will be performed with the HM (TRUCLEAR, Smith & Nephew, Andover, USA). The rotary blade is used for polypectomy and removal of residual placental tissue; the reciprocating blade is used for myomectomy. The blade has a window-opening at the end with cutting edges through which tissue is aspirated by means of a vacuum source. The removed tissue is discharged through the device, collected in a pouch and made available for pathology analysis.
Intervention Type
Procedure
Intervention Name(s)
Resectoscope
Intervention Description
Resectoscopy will be performed with a rigid 8.5 mm bipolar resectoscope (Karl Storz GmbH, Tuttlingen, Germany), equipped with a 0 or 30 degree optic. Normal saline is used for distension and irrigation of the uterine cavity. Fluid balance is closely monitored using a Hystero pump (Richard Wolf GmbH, Knittlingen, Germany) or Hysteromat pump (Karl Storz GmbH, Tuttlingen, Germany).
Primary Outcome Measure Information:
Title
Installation time and operating time.
Description
Installation time is defined as the time to set up the hysteroscopic instrumentation ready for use (time from start of setting up the instrumentation to start resection / morcellation). Operating time is defined as the time starting visual introduction of the hysteroscope until the time at which the procedure is completed and the hysteroscope is removed definitely. Times will be measured with a stop watch by a trained nurse.
Time Frame
the length of the operation
Title
Check for adhesions during follow-up.
Description
Ambulant diagnostic hysteroscopy is performed at 6 weeks postoperative follow-up.
Time Frame
After 6 weeks, during follow-up visit
Secondary Outcome Measure Information:
Title
Fluid deficit
Description
Fluid deficit in both procedures is the result of subtracting the outflow volumes from the inflow volumes as measured by the pump.
Time Frame
during the length of the operation
Title
complications and complaints
Description
During the postoperative hospital stay blood samples looking for electrolyte imbalances will only be taken when excessive fluid absorption is suspected based on fluid deficit (> 2500 mL for normal saline) and/or clinical symptoms. At 6 weeks postoperatively a standard visit is scheduled. Complications and complaints are recorded, and ultrasound is performed.
Time Frame
between operation until 6 weeks follow-up
Other Pre-specified Outcome Measures:
Title
Pregnancy rate
Description
number of pregnancies / number of women wishing to conceive
Time Frame
between the hysteroscopic removal of residual placental tissue and the first clinical pregnancy up to 7 years of follow-up
Title
Pregnancy outcome
Description
Pregnancy outcome (biochemical / EUG / miscarriage / fetal demise / live birth)
Time Frame
the first pregnancy subsequent to the hysteroscopic removal of residual placental tissue up to 7 years of follow-up
Title
Pregnancy complication
Description
Pregnancy complication (vaginal blood loss / preterm contractions / PPROM / pregnancy induced hypertension / preeclampsia / eclampsia / uterine rupture)
Time Frame
the first pregnancy subsequent to the hysteroscopic removal of residual placental tissue up to 7 years of follow-up

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with one or more intrauterine polyp(s) with a diameter ≥ 1 cm as seen on ultrasound, confirmed by saline infusion sonography and/or ambulant diagnostic hysteroscopy who are planned for hysteroscopic surgery. Patients with one or more intrauterine myoma(s) with a diameter ≤ 3 cm as seen on ultrasound, confirmed by saline infusion sonography and/or ambulant diagnostic hysteroscopy who are planned for hysteroscopic surgery. Patients with residual placental tissue as seen by ambulant diagnostic hysteroscopy who are planned for hysteroscopic surgery. Exclusion Criteria: Only polyps < 1cm (Note: intrauterine polyps < 1 cm are treated in an ambulatory setting). Myomas with a diameter > 3 cm (Note: Myomas > 3 cm are treated with resectoscopy) Type 2 myomas Visual or pathological (e.g. on biopsy) evidence of malignancy preoperatively or at the time of operation. Untreated cervical stenosis making safe access for operative hysteroscopy impossible as diagnosed preoperatively or at the time of operation. With a contra-indication for operative hysteroscopy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steven Weyers, MD, PhD
Organizational Affiliation
University Hospital, Ghent
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ghent University Hospital
City
Ghent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
Catharina Hospital Eindhoven
City
Eindhoven
ZIP/Postal Code
5602 ZA
Country
Netherlands

12. IPD Sharing Statement

Citations:
PubMed Identifier
26192235
Citation
Hamerlynck TW, Schoot BC, van Vliet HA, Weyers S. Removal of Endometrial Polyps: Hysteroscopic Morcellation versus Bipolar Resectoscopy, A Randomized Trial. J Minim Invasive Gynecol. 2015 Nov-Dec;22(7):1237-43. doi: 10.1016/j.jmig.2015.07.006. Epub 2015 Jul 17.
Results Reference
derived
Links:
URL
http://www.uzgent.be
Description
Related Info

Learn more about this trial

The Hysteroscopic Morcellator (HM).

We'll reach out to this number within 24 hrs